Soligenix confirms FDA orphan designation for active ingredient in SuVax

Soligenix announced that the Office of Orphan Products Development of the United States FDA has granted orphan drug designation to the active ingredient in SuVax, the subunit protein vaccine of recombinantly expressed Sudan ebolavirus glycoprotein, for “the prevention and post-exposure prophylaxis against SUDV infection.”